Page 119 - Case Lab Case Analysis
P. 119
When questioned on
Mylan's EpiPen price rise
chairman, Robert Coury
commented:
"….. that he was untroubled. He raised both his middle fingers and
explained, using colorful language, that anyone criticizing Mylan,
including its employees, ought to go copulate with themselves. Critics in
Congress and on Wall Street, he said, should do the same. And
regulators at the Food and Drug Administration? They, too, deserved a
round of anatomically challenging self-fulfillment."
Charles Duhigg https://www.nytimes.com/2017/06/04/business/angry-about-
epipen-prices-executive-dont-care-much.html
